Evolus Inc Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Evolus Inc (NASDAQ: EOLS) today and set a price target of $25. The company’s shares opened today at $9.09.

Chen commented:

“Takeaways from the quarter that support our thesis: 1) Evolus completed a comprehensive five-study clinical development program for DWP-450 and submitted a BLA to the FDA for U.S. regulatory approval. The filing was accepted for review., 2) The EMA accepted for review Evolus’s DWP-450 MAA for treatment of glabellar lines., 3) Health Canada accepted for review the company’s DWP-450 NDS for the treatment of glabellar lines., 4) Evolus raised $60MM through the sale of 5MM shares of common stock at a price of $12.00 per share in the company’s IPO. 5) If the uptake of DWP-450 is robust with a specialty sales force, Evolus may be able to achieve profitability without another equity raise. 6) Evolus completed all its responses to the FDA regarding its manufacturing observations and is waiting to hear back. An EIR would likely be its next communication with the Agency. 7) There has been no change to Evolus’s PDUFA date despite the manufacturing observations. But, we still expect U.S. approval around the summer of this year and EU approval at the end of the year. And, 8) Evolus is in the advanced stages of hiring more senior management ahead of the approval and launch of DWP-450.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -12.7% and a 33.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Evolus Inc has an analyst consensus of Moderate Buy, with a price target consensus of $23.

Based on Evolus Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and quarterly net profit of $4.45 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $3.74 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.